Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.53, demonstrating a +2.02% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.56%.

Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk ...

Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.

Earnings ESP of RXRX: Recursion Pharmaceuticals has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks ...

If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful starting point is understanding what the current market price might be ...

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

Nvidia sold its entire 7.71M share stake as ARK Invest bought 1.25M shares; RXRX swung 14% before closing 2% higher Wednesday.